Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alector, Inc. (ALEC : NSDQ)

• Company Description    Alector Inc. is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Its product portfolio includes AL001, AL101, Al002 and AL003 which are in clinical stage. Alector Inc. is headquartered in South San Francisco, California. Number of Employees: 238

• Price / Volume Information    Yesterday's Closing Price: $2.43 Daily Weekly Monthly 20 Day Moving Average: 841,106 shares Shares Outstanding: 110.36 (millions) Market Capitalization: $268.18 (millions) Beta: 0.64 52 Week High: $3.40 52 Week Low: $0.87 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 27.22% 28.89% 12 Week 100.83% 100.19% Year To Date 55.77% 62.60%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 131 OYSTER POINT BLVD. SUITE 600 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 415-231-5660 fax: - ir@alector.com http://www.alector.com

• General Corporate Information    Officers Arnon Rosenthal - Co-founder and Chief Executive Officer Neil Berkley - Chief Financial Officer and Chief Business Officer Grace Wong-Sarad - Vice President; Accounting Louis J. Lavigne - Director Elizabeth Garofalo - Director Peer Information Alector, Inc. (CORR.) Alector, Inc. (RSPI) Alector, Inc. (CGXP) Alector, Inc. (BGEN) Alector, Inc. (GTBP) Alector, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 014442107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 110.36 Most Recent Split Date: (:1) Beta: 0.64 Market Capitalization: $268.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.41 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.93 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 9.89% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.26 Price/Cash Flow: - Price / Sales: 12.74 EPS Growth vs. Year Ago Period: -1,600.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -88.50% vs. Previous Quarter: 91.32% ROE 12/31/25 - -191.85 09/30/25 - -123.02 06/30/25 - -112.06 ROA 12/31/25 - -38.98 09/30/25 - -27.48 06/30/25 - -26.37 Current Ratio 12/31/25 - - 09/30/25 - 3.76 06/30/25 - 3.78 Quick Ratio 12/31/25 - - 09/30/25 - 3.76 06/30/25 - 3.78 Operating Margin 12/31/25 - -679.16 09/30/25 - -156.03 06/30/25 - -142.10 Net Margin 12/31/25 - -679.16 09/30/25 - -156.03 06/30/25 - -142.10 Pre-Tax Margin 12/31/25 - - 09/30/25 - -155.96 06/30/25 - -142.04 Book Value 12/31/25 - - 09/30/25 - 0.57 06/30/25 - 0.71 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.17 06/30/25 - 0.13 Debt-to-Capital 12/31/25 - - 09/30/25 - 14.28 06/30/25 - 11.81

Powered by Zacks Investment Research ©